|Bid||11,230.00 x 200|
|Ask||11,240.00 x 34100|
|Day's Range||10,950.00 - 11,250.00|
|52 Week Range||99.40 - 11,250.00|
|PE Ratio (TTM)||144,102.56|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The bull market that kicked off in March 2009 should be on the front cover of AARP magazine. At age 8, the S&P 500 bull run is very old and very overvalued compared to its historical ratios. Given the less than stellar circumstances, how should you invest now?
GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.
A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed. A federal jury in Wilmington, Delaware on Tuesday found that Teva willfully infringed the patent in connection with its sales of a generic version of the drug with a label indicating it could be used for treating chronic heart failure. The jury rejected Teva's contention that the patent was invalid.